Skip to main content

PDE7A Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NB300-639

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NB300-639
NB300-639-0.025mg
NB300-639-0.05mg

Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

ELISA, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunoprecipitation, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

0.5 mg/ml

Product Specifications

Immunogen

Synthetic cyclic peptide (common to all PDE7A variants).

Reactivity Notes

Not yet tested in other species.

Localization

Mostly soluble cellular fractions.

Specificity

PDE7A

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for PDE7A Antibody

Western Blot: PDE7A Antibody [NB300-639]

Western Blot: PDE7A Antibody [NB300-639]

Western Blot: PDE7A Antibody [NB300-639] - Western Blot with PDE7A 1. Lungs 2. Kidney 3. Testis 4. Pancrease 5. Heart 6. Brain 7. Heart

Applications for PDE7A Antibody

Application
Recommended Usage

Immunoprecipitation

1:250

Western Blot

1:500
Application Notes
Immunoprecipitation and Western Blot: Detects a band of approximately 53 kDa (predicted molecular weight: 55 kDa). Optimal dilutions/concentrations should be determined by the end user.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

Tris/Glycine buffer, pH 7.4-7.8, HEPES,BSA 0.5%, glycerol 30%.

Preservative

0.02% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: PDE7A

The cyclic monophosphate nucleotides (cyclic adenosine monophosphate [cAMP] and cyclic guanosine monophosphate [cGMP]) are found ubiquitously in mammalian cells and act as second messenger transducers to effect the intracellular actions of a variety of G protein coupled receptors (GPCRs) for hormones, cytokines, and neurotransmitters. Cyclic nucleotides are important intracellular second messengers which play important role in a variety of signal transduction process. The cyclic nucleotides are hydrolyzed and compartmentalized by a family of enzymes called phosphodieterases. One of the many phosphodiesterases that compartmentalized and hydrolyze cAMP in T Lymphocytes are phosphodiesterase type 7. The cAMP specific phosphodiesterase type 7 (PDE7) family is comprised of 2 genes (PDE7A and PDE7B) each with multiple splice variants generated by RNA splicing and use of alternate initiation sites. PDE7A has two splice variants (PDE7A1 and PDE7A2). The two are divergent at the 5 prime end in human, and PDE7A1 is more hydrophobic. Like other PDEs, human PDE7A gene has 456 amino acids and migrates at an apparent molecular weight of 53 to 55 kDa on reduced SDS PAGE. The PDE7A has a significant conserved region of about 270 amino acids common to all PDEs at the carboxy terminal apparently serves as the catalytic domain. The amino terminal region of this protein is divergent and presumably accounts for the distinctive and regulatory properties unique to the individual PDE families. PDE7A protein showed significant homology to other cAMP dependent PDEs (23%) with in the catalytic domain. PDE7A is widely expressed in various tissues including skeletal muscle, T lymphocytes, brain and pancreas.

Long Name

High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A

Alternate Names

TM22

Entrez Gene IDs

5150 (Human); 18583 (Mouse); 81744 (Rat)

Gene Symbol

PDE7A

Additional PDE7A Products

Product Documents for PDE7A Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for PDE7A Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...